BioVie’s Bezisterim Aims to Reverse Brain Insulin Resistance and α-Synuclein Buildup
BioVie is developing lead candidate bezisterim (NE3107) to target neuroinflammation and insulin resistance in Parkinson’s patients, hypothesizing these drive neurodegeneration and dopaminergic deficits. The therapy is designed to enhance neuronal glucose metabolism, reduce α-synuclein aggregation, and address levodopa’s limitations of frequent dosing due to its short half-life.
1. Rethinking Parkinson’s Etiology
BioVie proposes that Parkinson’s disease stems not only from dopamine loss but from chronic neuroinflammation and insulin resistance in the brain. CEO Cuong Do argues impaired insulin signaling reduces neuronal energy supply, accelerates α-synuclein aggregation and triggers oxidative stress, positioning metabolic dysfunction as the root cause of neurodegeneration.
2. Bezisterim’s Dual Action
Bezisterim (NE3107) is designed to modulate inflammatory pathways and improve insulin sensitivity within neurons. By restoring insulin signaling, the drug aims to normalize glucose metabolism, support dopamine production, and inhibit toxic protein buildup linked to mitochondrial dysfunction.
3. Limitations of Levodopa
Levodopa remains the standard therapy for motor symptoms but requires multiple daily doses due to its short half-life, exposing patients to fluctuating control and “off” periods. BioVie believes bezisterim could offer more sustained symptom management by addressing underlying cellular dysfunction rather than only replenishing dopamine.
4. BioVie’s Development Path
Bezisterim serves as BioVie’s lead Parkinson’s candidate and is advancing toward clinical evaluation. The company plans to initiate studies assessing safety, biomarker changes in brain metabolism, and preliminary efficacy on motor and cognitive endpoints.